Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

722
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
722

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Duplication of the portal vein and the implications for procedural planning.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma.

Hong Kong medical journal = Xianggang yi xue za zhi·2024
Same author

Brain Metastasis Growth Kinetics: A Novel Prognosticator for Stereotactic Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Society, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, London, Ont. Sept. 15-18, 2011.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Heartburn as a Marker of the Success of Acid Suppression Therapy in Chronic Cough.

Lung·2021

Related Experiment Video

Updated: May 1, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.1K

Early Outcomes of Preoperative Short Course Radiotherapy With Simultaneous Integrated Boost and Response-adapted

B Chan1, N S M Wong1, B B W Wo1

  • 1Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|November 6, 2024
PubMed
Summary

Short course radiotherapy with simultaneous integrated boost for rectal cancer is feasible, showing high pathological complete response and R0 resection rates with low recurrence. Further research is needed to optimize this neoadjuvant treatment approach.

Keywords:
Capecitabine oxaliplatinneoadjuvantrectal cancershort course radiotherapysimultaneous integrated boost

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K

Related Experiment Videos

Last Updated: May 1, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Surgical Oncology

Background:

  • Limited evidence on dose escalation for neoadjuvant short course radiotherapy (SCRT) in rectal cancer.
  • Advancements in imaging and radiotherapy techniques enable exploration of enhanced treatment strategies.
  • Pathological complete response (pCR) is a key endpoint for evaluating treatment efficacy.

Purpose of the Study:

  • To evaluate the feasibility and outcomes of neoadjuvant SCRT with simultaneous integrated boost for rectal cancer.
  • To assess pathological complete response (pCR) rates, R0 resection, tumor downstaging, and toxicities.
  • To investigate the early pattern of recurrence following this treatment regimen.

Main Methods:

  • Retrospective review of 76 locoregional-advanced rectal cancer patients treated between January 2020 and December 2022.
  • Neoadjuvant SCRT with simultaneous integrated boost (5.5-6Gy/fraction, 5 daily fractions) followed by response-adapted chemotherapy.
  • Analysis of pCR rates, R0 resection, tumor downstaging, toxicities, and recurrence patterns.

Main Results:

  • 67 of 76 patients (88%) underwent curative surgery with 99% achieving R0 resection.
  • Pathological complete response (pCR) rate was 28% (19 patients); 55% experienced both T and N downstaging.
  • Grade 3+ treatment-related side-effects were low (e.g., proctitis 5%); surgical complications occurred in 15% of patients. No treatment-related deaths.
  • Median follow-up of 27 months revealed a low local recurrence rate of 6% (4 patients).

Conclusions:

  • Neoadjuvant SCRT with simultaneous boost is a feasible rectal cancer treatment with acceptable toxicity.
  • High R0 resection and pCR rates were observed in surgically treated patients.
  • Early data indicate a low locoregional recurrence rate, warranting further investigation into dose escalation and optimization.